DenialHelpUnderstand your prostate cancer denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
Start my appeal→
See how it worksThe denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for Prostate cancer?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a Prostate cancer appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the Prostate cancer appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under Prostate cancer?
Pluvicto (lutetium-177 vipivotide tetraxetan / 177Lu-PSMA-617) — FDA Mar 2022 PSMA+ mCRPC post-ARSI + post-taxane; FDA Mar 28, 2025 PSMAfore expansion to pre-chemo post-ARSI, Xofigo (radium-223 dichloride) — alpha-emitter for symptomatic bone-predominant mCRPC, no visceral mets, Xtandi (enzalutamide) — ARSI; FDA Aug 2012 mCRPC post-chemo, Sep 2014 pre-chemo, Jul 2018 nmCRPC, Dec 2019 mHSPC, Nov 2023 nmCSPC BCR high-risk, Erleada (apalutamide) — ARSI; FDA Feb 2018 nmCRPC (SPARTAN), Sep 2019 mHSPC (TITAN), Nubeqa (darolutamide) — ARSI; FDA Jul 2019 nmCRPC (ARAMIS), Aug 2022 mHSPC w/ docetaxel (ARASENS), Nov 2024 mHSPC monotherapy ARANOTE, Zytiga (abiraterone acetate) + prednisone — CYP17 inhibitor; FDA Apr 2011 mCRPC post-chemo, Dec 2012 pre-chemo, Feb 2018 mHSPC high-risk, Lynparza (olaparib) — PARP inhibitor; FDA May 2020 HRR-mutated mCRPC (PROfound); May 2023 + abiraterone BRCA-mutated 1L mCRPC (PROpel), Talzenna (talazoparib) + Xtandi — PARPi combo; FDA Jun 20, 2023 HRR-mutated 1L mCRPC (TALAPRO-2)
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.
Start my appeal→